2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1797

Seasonal Differences in the Disease Onset and the Exacerbation of Systemic Lupus Erythematosus
Abstract Number: 1798

Risk Factors for Osteonecrosis in Systemic Lupus Erythematosus: A Systematic Review
Abstract Number: 1799

Smoking, Antiphospholipid Antibodies and Thrombosis in SLE
Abstract Number: 1800

Prevalence of ECG Cardiovascular Abnormalities in Lupus Patients: A Novel Approach Using 5 ECG Elements
Abstract Number: 1801

Clinical Implications of Persistent Sinus Tachycardia in Systemic Lupus Erythematous: A Retrospective Study
Abstract Number: 1802

Prevalence of CMV in the Ohio State University Lupus Population
Abstract Number: 1803

General Features of SLE Patients Presenting with Autoimmune Hemolytic Anemia
Abstract Number: 1804

Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: a Single Centre Experience
Abstract Number: 1805

Factors Associated with Complete Remission in Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study in One Center
Abstract Number: 1806

Adherence to Treatment and Social, Educational Levels in Patients with Systemic Lupus Erythematosus
Abstract Number: 1807

Prevalence of Progressive Multifocal Leukoencephalopathy in Adults and Children with Systemic Lupus Erythematosus
Abstract Number: 1808

Frequency and Factors Associated with Thirty Day Hospital Readmissions Among Systemic Lupus Erythematosus Patients in a Community Hospital in the California Central Valley
Abstract Number: 1809

Influence of Solar Radiation in Cutaneous Manifestations of Lupus: Data from the Gladel Cohort
Abstract Number: 1810

Health Care Utilization Preceding Diagnosis of Systemic Lupus Erythematosus in Youth
Abstract Number: 1811

Systemic Lupus Erythematosus: Detailed Anatomy of a Cohort (follow-up for more than 35 years).

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].